Calcitonin gene-related peptide

Generic Name: Calcitonin gene-related peptide

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 83652-28-2

Unique Ingredient Identifier: JHB2QIZ69Z

Background: A 37-amino acid peptide derived from the calcitonin gene. It occurs as a result of alternative processing of mRNA from the calcitonin gene. The neuropeptide is widely distributed in the brain, gut, perivascular nerves, and other tissue. The peptide produces multiple biological effects and has both circulatory and neurotransmitter modes of action. In particular, it is a potent endogenous vasodilator.

As a potential drug, it has demonstrated in preclinical studies a profile that could make it an ideal anti-asthmatic drug candidate with bronchodilatory, bronchoprotecting and anti-inflammatory properties.

Indication: Investigated for use/treatment in myocardial infarction, heart disease, and asthma.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Research trends and hotspots in clinical trials of migraine in the past 20 years: bibliometric analysis

Migraine clinical trials research has increased from 2004-2023, analyzed via CiteSpace and VOSviewer, identifying the U.S. and Albert Einstein College of Medicine as leaders. Migraine, characterized by severe headaches and associated symptoms, remains a chronic issue despite drug availability.

neurologylive.com

4 months ago

Effectiveness of Rimegepant Further Displayed in Pooled Phase 3 Analysis

Rimegepant (Nurtec ODT) is a CGRP receptor antagonist approved for acute and preventive migraine treatment. A pooled analysis of 4 trials showed rimegepant 75 mg outperformed placebo in pain freedom and symptom relief at 2 hours, with low adverse events. Early intervention, consistent use, and flexibility in treatment optimize rimegepant's effectiveness. Reduced rescue medication use suggests lower risk of medication overuse headache. CGRP-targeting treatments are increasingly recommended as first-line for migraine management.

saba.ye

4 months ago

Breakthrough study reveals drug that could halt migraines before they start

A study reveals *ubrogepant* (brand name *Uberlevi*) may prevent migraines if taken at pre-migraine symptoms, with 65% reporting minimal pain 24 hours later. The drug targets CGRP protein, offering potential for proactive migraine management.

globenewswire.com

4 months ago

7MM Migraine Drug Market Forecast and Analysis to 2033

The 'Migraine: Seven-Market Drug Forecast and Market Analysis' report, added to ResearchAndMarkets.com's offering, forecasts the migraine market in the US, France, Germany, Italy, Spain, the UK, and Japan to grow from $9.2 billion in 2023 to $16.4 billion by 2033, driven by a 6.0% CAGR. The report covers epidemiology, treatment options, unmet needs, pipeline analysis, and market competition.

neurologylive.com

4 months ago

Tolebrutinib Shows Promise in Non-Relapsing Secondary Progressive MS, Fenebrutinib ...

Sanofi's phase 3 HERCULES study of tolebrutinib met primary endpoint of reducing disability in non-relapsing secondary progressive multiple sclerosis (nrSPMS). Roche's fenebrutinib showed significant relapse suppression in relapsing MS without disability change. FDA accepted Axsome Therapeutics' resubmitted NDA for AXS-07 for acute migraine treatment.

Related Clinical Trials:

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)

A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)

finance.yahoo.com

8 months ago

Pfizer (PFE) Q1 2024 Earnings Call Transcript

Pfizer's Q1 2024 earnings call highlighted a solid start to the year, with a focus on executing five strategic priorities: achieving world-class oncology leadership, delivering pipeline innovation, maximizing new product performance, expanding margins, and enhancing shareholder value. The company reported operational revenue growth of 11% excluding COVID products, with notable progress in oncology and other key areas. Pfizer also discussed its cautious optimism for the year ahead, emphasizing disciplined execution and strategic investments to drive growth and shareholder returns.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.